fondaparinux sodium


Aspen Pharmacare


Zuellig Pharma
Concise Prescribing Info
Fondaparinux Na
Listed in Dosage.
Dosage/Direction for Use
Prevention of venous thromboembolism (VTE): Orthopaedic & abdominal surgery 2.5 mg SC once daily, 1st dose should be no earlier than 6 hr post-op for at least 5-9 days. Patient at risk of thromboembolic complications 2.5 mg SC once daily for 6-14 days. Treatment of DVT & pulmonary embolism Body wt >100 kg 10 mg, 50-100 kg 7.5 mg, <50 kg 5 mg. Administer SC once daily for 5-9 days. Initiate vit K antagonists w/in 72 hr. Treatment of unstable angina/non-ST segment elevation MI 2.5 mg SC once daily up to 8 days. Treatment of ST segment elevation MI 2.5 mg once daily, 1st dose IV & subsequent doses SC, up to 8 days.
Hypersensitivity. Active clinically significant bleeding, acute bacterial endocarditis.
Special Precautions
Do not administer IM. Percutaneous coronary intervention. Increased risk of guiding catheter thrombus. Conditions w/ an increased risk of haemorrhage. Renal & severe hepatic impairment. History of heparin-induced thrombocytopenia. Latex allergy. Body wt <50 kg. Pregnancy & lactation. Childn <17 yr. Elderly.
Adverse Reactions
Anaemia, bleeding, purpura, oedema.
Drug Interactions
Drugs that may enhance the risk of haemorrhage eg, GPIIb/IIIa inhibitors or thrombolytics (except concomitant vit K antagonists used for VTE treatment). If co-administration is essential, close monitoring is recommended.
ATC Classification
B01AX05 - fondaparinux ; Belongs to the class of other antithrombotic agents.
Arixtra inj 2.5 mg/0.5 mL
10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in